Business

mass. mover

Biogen Idec slips after stock’s rating is cut

Weston-based Biogen Idec makes  drugs to treat neurodegenerative diseases, hemophilia, and autoimmune disorders.

Suzanne Kreiter/Globe Staff

Weston-based Biogen Idec makes drugs to treat neurodegenerative diseases, hemophilia, and autoimmune disorders.

Advertisement

Biogen Idec Inc., maker of the multiple sclerosis drug Tecfidera, fell after Citigroup cut the stock to “neutral” from “buy.” The shares had rallied 52 percent this year through Tuesday, Bloomberg News reported. Citi’s analyst cited concerns about regulatory protections for Tecfidera in the European Union when other drug makers submit applications to make generic versions.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com